Literature DB >> 12354367

Long-term Anticoagulation Therapy in Prevention of Stroke.

David Sherman1.   

Abstract

Long-term anticoagulation continues to be used and investigated as a means to prevent new or recurrent stroke. The best-established indications for long-term anticoagulation are cardiac abnormalities capable of producing intracardiac thrombi that may embolize into the brain or systemic circulation. The firmest cardiac indications are mechanical prosthetic heart valves, mitral stenosis with atrial fibrillation, and atrial fibrillation with additional features placing them at increased risk for stroke. These and other "major" cardiac potential sources of emboli should be considered as anticoagulation candidates unless the estimated risk of bleeding is prohibitive. A number of noncardiac potential causes of stroke are generally managed with long-term anticoagulation. These include arterial dissections, cerebral venous sinus thrombosis, the antiphospholipid antibody syndrome, and congenital and acquired coagulopathies. Recent randomized studies do not support the use of long-term anticoagulation for the prevention of recurrent stroke in patients with noncardioembolic stroke that is not due to the previously outlined disorders. Whether long-term anticoagulation is beneficial in the specific population of patients with major documented intracranial atherosclerotic stenosis is currently under investigation.

Entities:  

Year:  2002        PMID: 12354367     DOI: 10.1007/s11940-002-0008-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  16 in total

Review 1.  Managing oral anticoagulant therapy.

Authors:  J Ansell; J Hirsh; J Dalen; H Bussey; D Anderson; L Poller; A Jacobson; D Deykin; D Matchar
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 2.  Antithrombotic therapy in atrial fibrillation.

Authors:  G W Albers; J E Dalen; A Laupacis; W J Manning; P Petersen; D E Singer
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 3.  Antithrombotic agents in coronary artery disease.

Authors:  J A Cairns; P Théroux; H D Lewis; M Ezekowitz; T W Meade
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 4.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  G W Albers; P Amarenco; J D Easton; R L Sacco; P Teal
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 5.  Atrial fibrillation.

Authors:  R H Falk
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 6.  Hemorrhagic complications of anticoagulant treatment.

Authors:  M N Levine; G Raskob; S Landefeld; C Kearon
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

7.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

8.  A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

Authors:  J P Mohr; J L Thompson; R M Lazar; B Levin; R L Sacco; K L Furie; J P Kistler; G W Albers; L C Pettigrew; H P Adams; C M Jackson; P Pullicino
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

9.  Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke.

Authors:  A Cohen; C Tzourio; B Bertrand; C Chauvel; M G Bousser; P Amarenco
Journal:  Circulation       Date:  1997-12-02       Impact factor: 29.690

10.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

View more
  1 in total

1.  Cerebrovascular Disease in Pregnancy.

Authors:  Michael A. Sloan; Barney J. Stern
Journal:  Curr Treat Options Neurol       Date:  2003-09       Impact factor: 3.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.